Structural and functional analysis of the control region of the human DNA topoisomerase II alpha gene in drug-resistant cells.
We have previously shown that the DNA topoisomerase II alpha (topo II alpha) gene is down-regulated in VP16/VM26-resistant cells at the transcriptional level. To determine the DNA elements responsible for down-regulation, the transcriptional activities of luciferase reporter constructs containing various lengths of the promoter sequences were investigated by transient transfection of two resistant cell lines, KB/VP2 and KB/VM4. The transcriptional activities of the full-length promoter (-295 to +85) and of three deletion constructs (-197, -154 and -74 to +85) were significantly down-regulated in resistant cells. In contrast, the transcriptional activity of the minimal promoter (-20 to +85) in resistant cells was similar to that in parental KB cells. Furthermore, introduction of a mutation in ICE1 abolished the down-regulation of the topo II alpha promoter activity in drug-resistant cells. In vivo footprinting analysis of topo II alpha gene promoter revealed several specific protein-binding sites, a GC box, ICE1, ICE2 and ICE3. In vivo footprinting analysis also identified a cluster of hypersensitive sites. However, there was no marked difference in protein-binding sites between parental and resistant cells. To confirm our previous results, we have established the VP16-resistant cell lines T12-VP1 and T12-VP2 from T12 cells derived from human bladder cancer T24 cells stably transfected with the chloramphenicol acetyltransferase reporter gene driven by the topo II alpha gene promoter. The expression to topo II alpha was down-regulated in both cell lines. We also found that CAT gene expression was significantly decreased to one-fifth of that in T12 parental cells. These results suggest that the expression of the topo II alpha gene requires the binding of multiple factors to the core promoter and is down-regulated at the transcriptional level, probably through binding of a negative factor to ICE1 in drug-resistant cells.
Takano
H
H
Department of Molecular Biology, School of Medicine, Kitakyushu, Japan.
Ise
T
T
Nomoto
M
M
Kato
K
K
Murakami
T
T
Ohmori
H
H
Imamura
T
T
Nagatani
G
G
Okamoto
T
T
Ohta
R
R
Furukawa
M
M
Shibao
K
K
Izumi
H
H
Kuwano
M
M
Kohno
K
K
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents / Q000494:pharmacology; D001665:Binding Sites; D015152:Blotting, Northern; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D015500:Chloramphenicol O-Acetyltransferase / Q000096:biosynthesis / Q000235:genetics; D018983:DNA Footprinting; D004250:DNA Topoisomerases, Type II / Q000096:biosynthesis / Q000235:genetics*; D004268:DNA-Binding Proteins; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005047:Etoposide / Q000494:pharmacology; D017930:Genes, Reporter; D006801:Humans; D007527:Isoenzymes / Q000096:biosynthesis / Q000235:genetics*; D011401:Promoter Regions, Genetic; D014162:Transfection; D014407:Tumor Cells, Cultured
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; D007527:Isoenzymes; D005047:Etoposide; D015500:Chloramphenicol O-Acetyltransferase; D004250:DNA Topoisomerases, Type II